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IMPACT OF GASTROENTEROLOGY FELLOW INVOLVEMENT ON 
SCREENING COLONOSCOPY OUTCOMES IN PATIENTS WITH 
LONGSTANDING INFLAMMATORY BOWEL DISEASE 
NATHAN J. ROSENWALD 
ABSTRACT 
Inflammatory bowel disease (IBD) affects millions of people in 
the United States, with the number of diagnoses steadily rising. It has 
been associated with poor quality of life and a host of comorbidities. 
Most notably, IBD patients are at an increased risk of developing 
colorectal cancer (CRC). The American Gastroenterological Association 
(AGA) recommends that IBD patients with involvement of 1/3 or more 
of the colon undergo colonoscopy regularly to screen for CRC starting 
8 years after initial IBD diagnosis. Colonoscopy techniques for IBD-
related CRC screening are highly variable and differ widely between 
clinical practices. Currently, high-definition white-light colonoscopy 
(HD-WLC) and dye spraying chromoendoscopy (DCE) are both 
standard of care. The use of these technologies requires a high level of 
skill that is typically attained during clinicians’ 3-year gastroenterology 
(GI) fellowship. 	
This study intends to compare outcomes of screening 
colonoscopies performed by GI fellows and attending physicians in 
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patients with longstanding IBD (>8 years) and to assess the impact of 
GI fellow involvement on these procedures. Additionally, the current 
research intends to draw distinctions between HD-WLC and DCE 
procedures. The research was performed in the Division of 
Gastroenterology at Beth Israel Deaconess Medical Center (BIDMC) as 
part of a large randomized controlled trial (RCT) that aims to evaluate 
the comparative efficacy of HD-WLC and DCE. Patients were screened 
for study eligibility using relevant criteria and then randomized to 
undergo colonoscopy using HD-WLC technique or DCE technique. 	
Data from 128 procedures were included in the study. Of these 
procedures, 59 (46.1%) were attending-performed procedures while 
69 (53.9%) were fellow-performed, attending-supervised procedures. 
Of the attending-performed procedures, 30 (50.8%) were performed 
using the DCE technique and 29 (49.2%) were performed using the 
HD-WLC technique. Of the fellow-performed, attending-supervised 
procedures, 32 (46.4%) were performed using the DCE technique 
while 37 (53.6%) were performed using the HD-WLC technique. 
Fellow-performed, attending-supervised procedures were associated 
with longer total procedure time (TPT) and increased intra-procedure 
administration of sedation medications without superior lesion 
detection. Thus, fellows appear to be on par with attendings in terms 
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of lesion detection but this level of proficiency comes at the cost of 
increased TPT. Assessing the short-term and long-term impacts of this 
could be a valuable area of future investigation. Also, DCE procedures 
took longer for all clinicians to perform, especially fellows, and are not 
associated with enhanced lesion detection. Further research is needed 
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Inflammatory Bowel Disease 	
	
Inflammatory bowel disease (IBD) is an umbrella term used to 
describe diseases that are characterized by chronic inflammation of the 
gastrointestinal (GI) tract. Specifically, Crohn’s disease (CD) and 
Ulcerative Colitis (UC) fall under the category of IBD. IBD has been 
associated with poor quality of life and a host of comorbidities that 
frequently result in hospitalization and the need for surgical 
interventions (Cohen, 2002). Symptoms of IBD can be extremely 
painful for patients and include diarrhea, fatigue, abdominal cramping, 
blood in the stool, reduced appetite, and weight loss. 	
IBD is quite prevalent in the United States and the number of 
patients diagnosed with IBD has been steadily rising. In 1999, 
approximately 1.9 million adults in the United States had been 
diagnosed with IBD. This represented approximately 0.9% of adults in 
the United States at the time. As of 2015, approximately 3.1 million 
adults in the United States had been diagnosed with IBD, representing 
1.3% of the population (Dahlhamer, Zammitti, Ward, Wheaton, & 
Croft, 2016). Beyond the rise in IBD cases seen in the United States in 
the past twenty years, the number of IBD diagnoses have been 
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steadily rising for almost a century. Driving forces for this 
phenomenon may include the population’s movement away from an 
agricultural lifestyle, increased consumption of processed fast foods, 
and more frequent disruptions to sleep caused by factors such as 
stress and employment obligations. Other areas of the world, 
specifically Asia, which historically did not have IBD incidence on par 
with the United States, have seen an uptick in cases that is likely 




 The term “ulcerative colitis” was first coined by London physician 
Samuel Wilks in the year 1859. Wilks’s forty-two-year-old female 
patient who died after months of diarrhea and fever was found on 
autopsy to have transmural ulcerative inflammation in the colon and 
terminal ileum (Wilks, 1859). Interestingly, by modern naming 
conventions, the 1859 “ulcerative colitis” case reported by Wilks would 
now be classified as CD (Kirsner, 2001). The first “true” case of UC 
(based on modern naming standards) was described in 1875 in a 
female patient who died after severe bloody diarrhea. Inspection of her 
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large bowel on autopsy showed extensive ulceration and inflammation 
throughout the colon (Wilks & Moxon, 1875). 	
Unlike CD, which could occur at any location in the small or large 
bowel, UC specifically is characterized by continuous colonic mucosal 
inflammation that begins at the rectum and extends proximally. 
Patients with UC usually present with bloody diarrhea and urgency. 
Occasionally, these symptoms are associated with a low-grade fever 
and/or weight loss. Symptoms of UC usually start gradually and 
progress for a number of weeks until the patient presents for 
treatment (Ford, Moayyedi, & Hanauer, 2013). However, some 
patients may not present for treatment until months or even years 
after the initial onset of UC symptoms. Factors that are associated with 
longer duration from initial onset of symptoms until initial presentation 
for treatment include mild severity and/or limited location of disease, 
as well as social determinants of health (SDOH), such as poor access 
to healthcare services or lack of insurance coverage (Burgmann et al., 
2006). 	
 UC remains idiopathic, although it appears that the main risk 
factors for the development of UC are gut microbiome changes and 
disruption in colonic mucosa (Danese & Fiocchi, 2011). These changes 
are most commonly secondary to GI infections and/or use of 
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nonsteroidal anti-inflammatory drugs (NSAIDs), antibiotics, oral 
contraceptives, or hormone replacement therapy medications (Loftus, 
2004; Ananthakrishnan et al., 2012; Shaw, Blanchard, & Bernstein, 
2011; Cornish et al., 2008; Khalili et al., 2012). Curiously, cigarette 
smoking seems to have a protective effect against the development of 
UC and smoking cessation is associated with an increased risk of 
developing UC. However, given the well-documented severe 
detrimental health impact of smoking cigarettes, GI clinicians counsel 
patients to quit smoking (Mahid, Minor, Soto, Hornung, & Galandiuk, 
2006). Diet does not appear to have any identifiable impact on the 
development of UC (Hart et al., 2008). 	
 In addition to the environmental risk factors associated with the 
development of UC, there appears to be a genetic component as well. 
UC is commonly seen in patients with Jewish heritage and rarely seen 
in African American or Hispanic populations (Ng et al., 2013). 
Research into the genetic foundations of the development of UC is still 
in the early stages, but currently HLA-DqA1 variants appear to be 
most linked to the development of UC (Ventham, Kennedy, Nimmo, & 
Satsangi, 2013). More research needs to be done in this area to 
further elucidate the family history component of UC. Based on the 
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current research, only about 10% to 25% of IBD patients have a first-
degree relative (FDR) with the disease (Ng et al., 2013). 	
 Diagnosis of UC relies on clinical correlation of symptoms and 
laboratory test results with evidence found on endoscopy. In cases of 
possible UC, laboratory tests can be used to rule out other potential 
diagnoses. Elevated inflammatory markers in blood, such as 
erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), 
are common in cases of UC. But, patients who suffer from UC can 
sometimes have normal values on these laboratory tests. Markers of 
intestinal inflammation, such as fecal lactoferrin and fecal calprotectin, 
could be more sensitive but are not specific to UC (Feuerstein & 
Cheifetz, 2014). In practice, after a patient presents to the GI clinician 
with symptoms that are classic for UC, and laboratory test results are 
suggestive of UC, an endoscopy (colloquially termed “colonoscopy”; 
this term is discussed further below) is performed. In cases of UC, the 
endoscopist is usually able to visualize gross evidence of colonic 
inflammation beginning at the rectum and extending proximally. 
Nevertheless, biopsy specimens are used to confirm the diagnosis. 
Histological findings that are indicative of UC include lymphocyte, 
granulocyte, and plasma cell infiltrates in the mucosal layer and 
disruption of the crypt architecture (Appleman et al., 2008). 	
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 UC severity can range from mild, with symptoms that may even 
go unnoticed by the patient, to fulminant, with symptoms that 
drastically impact patient lifestyle and quality of life. Mild classification 
is characterized by 3 or fewer stools per day, no signs of systemic 
toxic effects, and inflammatory markers within the normal range. 
Moderate classification is characterized by 4 or more bloody stools per 
day and nominal indications of systemic toxic effects. Severe 
classification is characterized by 7 or more bloody stools per day and 
some signs of systemic toxic effects, such as anemia and tachycardia. 
Fulminant classification is characterized by 11 or more bloody stools 
per day and obvious signs of systemic toxic effects, including the need 
for blood transfusions and colonic dilation seen on imaging (Feuerstein 
& Cheifetz, 2014). Additionally, UC can be described by the location of 
the disease. Proctitis denotes disease that is only found in the rectum. 
Proctosigmoiditis denotes disease that is found in the rectum and 
sigmoid colon. Left-sided colitis indicates disease that is found in the 
colon beginning at the rectum and extending until the splenic flexure. 
Extensive colitis, also known as pancolitis, describes disease that is 
found throughout the entire colon, beginning at the rectum and 
extending beyond the splenic flexure (Ford et al., 2013). 	
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 In some cases, patients may experience extra-intestinal 
manifestations (EIMs) associated with their UC. Like UC, EIMs are 
inflammatory processes. EIMs typically affect the skin, eyes, liver, and 
joints. Primary sclerosing cholangitis (PSC) is one of the most common 
EIMs of UC (Hirschfield, Karlsen, Lindor, & Adams, 2013). PSC is a 
chronic liver disease characterized by inflammation of the bile ducts, 
resulting in portal hypertension and cirrhosis. Another common EIM is 
Ankylosing Spondylitis (AS), which is a form of arthritis that primarily 
affects the spine and leads to chronic stiffness and pain. Other EIMs 
include osteoporosis, psoriasis, uveitis, and scleritis (Williams, Walker, 
& Orchard, 2008). 	
 Treatment of UC classically follows a step-up approach and is 
flexible to patient and provider preferences. The goals of UC therapy 
are to achieve clinical remission and induce mucosal healing. Lately, 
an emphasis has been placed on not only achieving clinical remission— 
meaning that the patient becomes free from symptoms of the 
disease—but also achieving deep remission, meaning that evidence of 
the disease is no longer visible on endoscopy. Initial research shows 
that deep remission is associated with decreased risk of UC flares, 
colorectal cancer (CRC), and future need for surgical interventions 
(Lichtenstein & Rutgeerts, 2010). Therefore, in a broader sense, 
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treatment is intended to improve patient quality of life and reduce the 
risk of complications from UC. 5-aminosalicylates (5-ASAs), which can 
be administered orally, rectally, or in combination, have shown to be 
the best treatment option for mild and moderate cases of UC (Ford, 
Khan, Achkar, & Moayyedi, 2011). In cases of severe UC, or when 
symptoms persist despite treatment with 5-ASAs, corticosteroids are 
used to induce remission. Then, anti-tumor necrosis factor α (anti-
TNF) agents or thiopurines are used to maintain remission. In some 
cases, such as when corticosteroids are contraindicated, anti-TNF 
agents or thiopurines are used as initial treatment. Research shows 
that infliximab, a common anti-TNF agent, used together with 
azathioprine, a thiopurine, is more effective than either treatment 
used alone. In certain severe or fulminant cases of UC, or in cases of 
CRC, surgical intervention in the form of a total colectomy is used as a 
last resort. About 10% to 15% of UC patients will require this type of 




 CD was first described by Burrill B. Crohn, Leon Ginzburg, and 
Gordon D. Oppenheimer in 1932. Until that point, diseases of the small 
 
9 
bowel were often confused and generally indistinguishable. Generally, 
these conditions were considered to be intestinal tuberculosis. Crohn 
and his colleagues followed 14 patients with similar symptoms, 
including abdominal cramping, diarrhea, fever, and fatigue. Pathology 
results showed “necrotizing and cicatrizing inflammation” in the 
terminal ileum of each of these patients (Crohn, Ginzburg, & 
Oppenheimer, 1932). Therefore, Crohn and his colleagues termed this 
new disease entity “regional ileitis.” The name was later changed to 
the more general “Crohn’s disease” when similar cases were reported 
in other areas of the small bowel (Actis, Pellicano, Fagoonee, & 
Ribaldone, 2019). 	
 Unlike UC, which is characterized by continuous colonic mucosal 
inflammation beginning at the rectum and extending proximally, CD 
can affect any part of the GI tract from the mouth to the anus. 
Patients with CD may present with patches of inflammation in the GI 
tract known as “skip lesions.” About half of CD patients have 
concurrent inflammation in the terminal ileum and colon, with the 
other half having involvement solely in the small bowel or colon. CD is 
subclassified into 3 distinct categories based on phenotype. 
Inflammatory CD is characterized by patchy inflammation in the small 
or large bowel with no signs of strictures or fistulae. This type of 
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disease could progress to stricturing CD due to irreversible fibrosis and 
luminal narrowing secondary to chronic inflammation in the GI tract. 
Ongoing transmural inflammation could lead to the development of 
fistulae seen in cases of fistulizing CD (also known as penetrating CD). 
Fistulae could form between the GI tract and adjacent organs such as 
the vagina and bladder. Incomplete fistula formation may lead to 
intra-abdominal abscesses (Cheifetz, 2013). 	
 Many symptoms of CD, including abdominal pain, weight loss, 
fatigue, and fever are similar to UC. However, bloody stool is most 
often associated with UC specifically and is only a symptom of CD in its 
most severe cases. In cases of stricturing CD, patients sometimes 
present with small bowel obstructions caused by the luminal narrowing 
associated with the disease. In cases of fistulizing CD, patients may 
present with urinary tract infections or drainage from the skin. As with 
UC, diagnosis of CD is based on clinical correlation of symptoms and 
laboratory test results with evidence found on endoscopy (Baumgart & 
Sandborn, 2012). The possible involvement of EIMs is a key 
commonality between UC and CD. 	
 Similar to UC, the exact pathogenesis of CD remains unknown 
and the main environmental risk factor appears to be gut dysbiosis 
(Loftus, 2004). However, unlike UC in which cigarette smoking 
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appears to have a protective effect, patients who smoke cigarettes are 
two times as likely to develop CD compared to those who do not 
smoke (Mahid, Minor, Soto, Hornung, & Galandiuk, 2006). 
Additionally, unlike UC in which diet does not appear to have any 
impact on development of the disease, initial evidence indicates that 
diets high in sugar, fats, oil, and meat may be associated with 
development of CD, while high fiber diets may decrease the risk of CD 
(Amre et al., 2007; Sakamoto et al., 2005). This research is in its 
early stages, so further evidence is needed to clarify the role of diet in 
the development of CD. 	
 Like UC, CD is seen more commonly in patients with Jewish 
heritage and seen less often in African American and Hispanic patients. 
Heterozygous changes to the NOD2 locus of chromosome 16 have 
been shown to increase risk of CD by 2 to 4 times. Homozygous 
changes at this locus increase risk of CD by 20 to 40 times (Philpott & 
Viala, 2004). In addition to this locus, hundreds of other foci have 
been associated with the development of CD while more continue to be 
elucidated. 	
 In cases of colonic CD, endoscopy typically reveals patchy 
inflammation adjacent to normal mucosa. However, because CD could 
manifest in areas of the GI tract that are not accessible on standard 
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colonoscopy, other techniques are commonly used to reach a 
diagnosis. In certain cases, capsule endoscopy is used to visualize the 
entire GI tract. Additionally, imaging studies of the small bowel, 
including computed tomography enterography (CTE) and magnetic 
resonance enterography (MRE), are often employed to reach a 
diagnosis of CD (Dambha, Tanner, & Carroll, 2014).  	
 As diagnostic techniques progress and the efficacy of drug 
therapies in treating CD continues to improve, the need for surgical 
intervention has declined. Still, more than half of CD patients need 
surgery during the course of their disease (Frolkis et al., 2013). In 
cases of stricturing CD, surgery is sometimes necessary to resect 
strictures because no medical therapy exists to reverse these intra-
luminal changes (Rieder et al. 2016). Bowel resection is sometimes 
indicated in cases of fistulizing CD when fistulae cause direct 
complications (Gionchetti et al., 2017). In all cases, the need for 
surgical intervention and the type of procedure performed is dictated 
by the exact manifestation of the disease.  
	
IBD as a Risk Factor for Colorectal Cancer	
 Patients suffering from IBD are at an increased risk of 
developing CRC compared to the overall population. Even though IBD-
 
13 
related CRC accounts for less than 2% of all CRC diagnoses, it is the 
most severe complication of IBD and leads to almost 15% of deaths in 
IBD patients. Factors associated with an increased risk of developing 
IBD-related CRC are early initial onset of symptoms, younger age at 
diagnosis of IBD, severity of disease, and previous colonic mucosal 
dysplasia. Research indicates that 5-10% of IBD patients develop CRC 
after 20 years of disease, while 12-20% of IBD patients develop CRC 
after 30 years of disease (Munkholm, 2003). 	
 As for UC, patients diagnosed with left-sided colitis or pancolitis 
are most at risk for developing IBD-related CRC. PSC is also a 
significant factor that increases risk of developing IBD-related CRC 
(Feuerstein & Wasan, 2011). Among CD patients, involvement of more 
than one third of the colon significantly increases the risk of 
developing IBD-related CRC (Baumgart & Sandborn, 2012). 	
 Due to their increased risk of developing CRC, the American 
Gastroenterological Association (AGA) recommends that IBD patients 
begin undergoing colonoscopy to screen for CRC starting 8 years after 
initial IBD diagnosis. Once in the screening protocol, the duration 
between subsequent screening colonoscopies is dependent on the 
exact IBD diagnosis and presence of other risk factors. For example, 
IBD patients with PSC are recommended to undergo screening 
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colonoscopy every year while IBD patients at relatively low risk of 
developing CRC may be counseled to wait 3 years between screening 
colonoscopies (Farraye, Odze, Eaden, & Itzkowitz, 2010). 	
	
	
Figure 1: Cumulative risk of developing CRC in UC (Adapted 
from Munkholm, 2003)  
Colonoscopy	
 In gastroenterological practice, endoscopy is the main tool used 
to screen for dysplasia and CRC. To be precise, “endoscopy” refers to 
any procedure in which a specialized tool, called an endoscope, is 
passed through an orifice (i.e., mouth or rectum) to visualize internal 
organs. Today, the term “endoscopy” is colloquially used to describe 
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an upper endoscopy, also known as esophagogastroduodenoscopy 
(EGD), in which the endoscope is passed through the mouth to 
visualize the esophagus, stomach, and proximal portion of the small 
bowel. So, the term “colonoscopy” has come to refer to an endoscopic 
procedure in which the endoscope (in this case referred to as 
colonoscope), is passed through the anus to visualize rectum, colon, 
and distal portion of the small bowel (Steele, 2020). 	
 The 1950s invention of the modern endoscope is attributed to 
Harold Hopkins, who created a flexible fiberoptic bundle that was able 
to transmit an optical image. Before this invention, clinicians mostly 
relied on patient history and physical examination to make diagnoses. 
Or, in some cases, visualization of internal organs was made possible 
by surgical exploration. The invention of the endoscope revolutionized 
diagnosis and treatment of GI diseases, specifically IBD. As technology 
has progressed, endoscopic technology has drastically improved. 
Today, modern endoscopes feature camera technology that is able to 
transmit real-time digital images to monitors in the procedure room. 
Additionally, a variety of endoscope adjuncts are available to give 
clinicians the ability to take histological samples and treat problems 
endoscopically. For instance, colonoscope adjuncts allow clinicians to 
retrieve biopsy specimens and resect polyps. The diagnostic 
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capabilities and treatment options made possible by endoscopy are 












Colonoscopy techniques for detecting dysplasia and screening for 
IBD-related CRC are highly variable and differ widely between clinical 
practices. In recent history, standard-definition white-light colonoscopy 
(SD-WLC) with random colonic mucosal biopsies was used most often 
in IBD-related CRC screening (Eaden & Mayberry, 2002). But, this 
technique is time-consuming and very costly. The advent of high-
definition white-light colonoscopy (HD-WLC), with improved resolution 
compared to SD-WLC, has led to an increased ability to visually detect 
colonic mucosal dysplasia and retrieve targeted biopsies, thus 
decreasing the cost of screening procedures. In fact, HD-WLC with 
targeted biopsies is becoming the screening method of choice for 
many GI clinicians compared to taking random mucosal biopsies 
(Gasia et al., 2016). 	
 To enhance visual detection of dysplasia and the ability to take 
targeted biopsies when screening patients for IBD-related CRC, a 
technique called dye spraying chromoendoscopy (DCE) has been 
developed. Using this technique, a dye sublimation of indigo carmine is 
applied to the colonic mucosa. Indigo carmine, or 5,5′-indigodisulfonic 
acid sodium salt, is an organic salt that is used in a variety of 
applications, most notably in solution as blue food coloring. When 
sprayed on colonic mucosa, this contrast dye highlights subtle 
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architecture changes and could improve the sensitivity of visual 
dysplasia detection (Rutter et al. 2004). While it is well established 
that DCE is equally safe compared to SD-WLC and HD-WLC, the exact 
efficacy of this technique in screening for IBD-related CRC is still being 
elucidated. The usefulness of this technique is especially called into 
question given the ever improving resolution offered by the latest 




Figure 3: Usefulness of 
DCE; (a) disruption of 
mucosal fold is visible but 
whole lesion is unclear, (b) 
depressed lesion is clearly 
identified after dye 
spraying, (c) slightly 
elevated lesion is evident 
but whole lesion is not 
obvious, (d) elevated lesion 
is readily detected after 










Regardless of the exact colonoscopy technique employed in 
screening for IBD-related CRC, adequate bowel preparation is essential 
to an effective procedure. In an ideal scenario, bowel preparation 
should empty all fecal material from the colon without causing 
histologic changes in the colonic mucosa, dehydration, or patient 
discomfort. Inadequate bowel preparation is associated with 
incomplete colonoscopy and an inability to visually detect dysplasia. 
Common bowel preparation agents include high volume polyethylene 




The use of endoscopy technology requires a high level of skill 
that is typically attained during clinicians’ GI fellowship. At Beth Israel 
Deaconess Medical Center (BIDMC), the site at which the current 
research was conducted, GI fellowship consists of 3 years of training, 
as is typical of GI fellowship programs in the United States. Training 
entails fellows gaining experience in the areas of inpatient GI care, 
outpatient GI care, hepatology, research, and endoscopy. Endoscopic 
training is integral to all aspects of fellows’ overall GI education and is 
foundational to their careers as GI clinicians. In the first year of 
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fellowship, it is understood that GI fellows require constant supervision 
and frequent assistance from an attending GI physician while 
executing all procedures. In the second year, GI fellows are expected 
to be able to execute routine procedures with minimal input from the 
attending GI physician, while still requiring frequent assistance during 
more advanced procedures. By the third year of fellowship, GI fellows 
typically execute routine procedures without input from the attending 
GI physician. During this year, GI fellows gain competence in 
advanced procedures to the point that minimal assistance is needed 
from the attending GI physician. 	
BIDMC also offers a one-year subspecialty fellowship in IBD for 
physicians who have already completed a standard GI fellowship. 
These fellows gain additional endoscopy training while learning 
diagnostic and treatment strategies that are specific to IBD patients. 
For purposes of the current research, BIDMC IBD fellows are referred 
to as “4th year fellows” even though most of them completed their 3-
year GI fellowships at other institutions. The majority of time spent on 
endoscopy training during GI fellowship at BIDMC happens in the first 
and third years of fellowship, with the second year of fellowship having 
the fewest required hours of endoscopy training (Beth Israel 






Figure 4: General structure of GI fellowship at BIDMC (Adapted 








Goals of the Present Study	
The current research is primarily intended to compare GI fellow 
and attending outcomes from screening colonoscopies in which the 
patient suffers from longstanding IBD (>8 years) and to assess the 
impact of GI fellow involvement on these procedures. Previous 
research indicates that GI-fellow-performed, attending-supervised 
screening colonoscopies are associated with an average total 
procedure time (TPT) that is nearly double that of attending-performed 
screening procedures, without any enhanced lesion detection 
(Chapman, Hossack, Hanan, & Kim, 2010). However, this research 
looked at a general patient population, instead of the IBD-specific 
population of the current study. Also, this research did not account for 
differences in HD-WLC and DCE procedures and did not assess other 
outcomes included in the present study. Therefore, as a secondary 
aim, the current research intends to draw distinctions between HD-
WLC and DCE procedures and to expand the breadth of outcomes 
studied beyond TPT. 	
The data obtained for the present study is part of a large 
randomized controlled trial (RCT) in the Division of Gastroenterology at 
BIDMC that aims to evaluate the comparative efficacy of HD-WLC and 
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DCE. Data was collected during the period beginning May 2019 








 The Division of Gastroenterology at BIDMC performs thousands 
of procedures per year in the multiple procedure centers that it 
operates throughout the greater Boston, MA, area. The current 
research uses data from procedures that were performed at three of 
those centers: East Campus Endoscopy Center, in Longwood Medical 
Area, Boston, MA; West Procedure Center, in Longwood Medical Area, 
Boston, MA; and Boston Endoscopy Center (BEC), in Wellesley, MA. 	
 Before arrival for colonoscopy, patients were screened for study 
eligibility using the following criteria:	
1. Duration of IBD. The current study only includes patients 
suffering from longstanding IBD with more than 8 years 
since initial onset of symptoms.  
2. Extent of IBD. The current study only includes patients 
with IBD known to extend beyond ⅓ of the colon. Patients 
suffering from proctitis, regardless of the duration, were 
excluded from the study.  
3. Prior GI Surgeries. Patients who had undergone a large 
resection of the bowel were excluded from the study. 
Patients with a history of other GI surgeries, such as 
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cholecystectomy or appendectomy, were included in the 
study. These aspects of patient history were documented 
in the study database.  
 When it was determined that a patient met all study criteria, the 
attending physician who was scheduled for the time and location of the 
procedure was alerted to the patient’s eligibility. While obtaining 
informed consent for the procedure itself immediately before 
performing the colonoscopy, which is done in all cases, the clinician 
(attending or fellow) set to perform the procedure requested the 
eligible patient’s informed consent to be enrolled in the present study. 
Obtaining informed consent involved the clinician describing the aims 
of the research as well as any possible harms or benefits the patient 
may encounter as result of being enrolled in the study. 	
After obtaining informed consent from the patient, the clinician 
retrieved an envelope from a predetermined location within the 
procedure center. Block randomization was done by one researcher 
not involved in the study procedures prior to the start of the research 
to keep the clinician and patient blinded to the randomization order. 
Each envelope was labeled with a randomization number 1-500 and 
contained a corresponding randomization form that directed the 
clinician to perform one of the two following colonoscopy techniques:	
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1. HD-WLC with random biopsies taken every 10 cm 
during withdrawal from the colon 
or	
2. DCE with targeted biopsies taken as determined 
necessary by the clinician performing the procedure.  
This randomization form doubled as a worksheet to be used during the 
procedure, and included fields for the patient’s medical record number 
(MRN) and procedure start time, cecum reached time, and end of 






Figure 5: Example of randomization form: Includes randomization 
number (top left), field for patient’s MRN (top right), type of procedure 




Of note, the standard colonoscopy technique of intubating to the 
cecum and inspecting for dysplasia during withdrawal was performed 
similarly in both conditions of this study. Additionally, in both 
conditions the clinician was able to perform polypectomies and biopsy 
visible dysplasia as deemed necessary by clinical judgement. The main 
difference between the two techniques is that the HD-WLC condition 
involved retrieving random biopsies at prescribed locations within the 
colon during withdrawal while DCE did not involve any random 
biopsies. Instead, during DCE procedures, an indigo carmine solution 
was sprayed throughout the entire colon during withdrawal and 
targeted biopsies were obtained in areas of visible dysplasia. 	
During the procedure, each patient was sedated using one of two 
techniques, as determined by the patient’s history and clinician 
judgement:	
1. Moderate sedation, also known as conscious sedation, 
which could be administered by a registered nurse 
(RN), involves intra-procedure titration of fentanyl and 
midazolam to achieve a decreased level of patient 




2. Monitored anesthesia care (MAC), administered by an 
anesthesiologist, involves a pre-procedure bolus and 
intra-procedure titration of propofol to bring the patient 
to a sleep-like state (Das & Ghosh, 2015).  
Data from each procedure was entered and stored in a Redcap 
database using its cloud-based software. Additional patient 
information, including demographic details and IBD history, were 
retrieved from patient records and included in the database. Data from 
the pathology report was entered in the database once it became 








 The present study includes data from 128 procedures. Of these 
procedures, 59 (46.1%) were attending-performed procedures while 
69 (53.9%) were fellow-performed, attending-supervised procedures. 
Of the attending-performed procedures, 30 (50.8%) were performed 
using the DCE technique and 29 (49.2%) were performed using the 
HD-WLC technique. Of the fellow-performed, attending-supervised 
procedures, 32 (46.4%) were performed using the DCE technique 





DCE 30 (50.8%) 32 (46.4%) 
HD-
WLC 
29 (49.2%) 37 (53.6%) 
Total 59 69 
	




 The majority of fellow-performed, attending-supervised 
procedures were executed by third-year fellows (38 procedures, 
55.1%); 14 procedures (20.3%) were performed by second-year 
fellows; 14 procedures (20.3%) were performed by fourth-year 
fellows; and only 3 procedures (4.3%) were performed by first-year 
fellows. 	
	
Fellowship Year Number of Procedures Performed 
1 3 (4.3%) 
2 14 (20.3%) 
3 38 (55.1%) 
4 14 (20.3%) 
Total 69 
 	
Table 2: Breakdown of fellow-performed, attending supervised 
procedures by fellowship year	
	
 The median age of patients enrolled in the study was 50 years 
old (Mean 49.98, SD 14.64). As for sex, 79 (61.7%) of the patients 
were male and 49 (38.3%) of the patients were female. Regarding 
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disease history, 80 (62.5%) patients had a history of UC, 43 (33.6%) 
of patients had a history of CD, and 5 patients (3.9%) had a history of 
indeterminate IBD. The mean duration of IBD symptoms for all 
patients enrolled in the study was 17.8 years (SD 9.5). As for family 
history, 20 patients (15.6%) had a family history of IBD and 19 
patients (14.8%) had a family history of CRC.  
 
	
IBD Diagnosis  Number of Patients 
UC 80 (62.5%) 
CD 43 (33.6%) 
Indeterminate 5 (3.9%) 
Total 128 
	Table 3: Breakdown of IBD diagnoses of patients enrolled in 
study 	
  
TPT for all fellow performed, attending-supervised procedures 
was on average 11.6 minutes (95% CI 7.3 - 15.9, p<0.001) longer 
than attending-performed procedures. When adjusting for history of 
dysplasia, time of day (morning vs. afternoon), type of sedation 
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(moderate sedation vs. MAC), and procedure technique (DCE vs. HD-
WLC), fellow involvement was associated with an average TPT increase 
of 12.3 minutes (95% CI 7.5 - 16.98, p<0.001). These longer 
procedure times were associated with increased intra-procedure 
administration of sedation medications. On average, patients 
undergoing moderate sedation in fellow-performed, attending-
supervised procedures received 16.1 mcg more fentanyl than patients 
in attending-performed procedures. Patients undergoing MAC in fellow-
performed, attending-supervised procedures received on average 93.3 
mg more propofol than patients in attending-performed procedures. 	
Fellow involvement in HD-WLC procedures was associated with 
an average increased TPT of 10.96 minutes (95% CI 3.84 - 16.48, 
p=0.003). Fellow involvement in DCE procedures was associated with 
an average increased TPT of 11.93 minutes (95% CI 0.44 - 23.42, 
p=0.04). Amongst all clinicians, TPT was longer in DCE procedures 








Procedure Type Average Increased Length 
DCE 11.93 minutes 
HD-WLC 10.96 minutes 
		
Table 4: Average increased procedure length associated with 
fellow involvement	
		
There was no significant difference between fellows and 
attendings regarding the number of lesions detected. Fellows detected 
at least one lesion in 31/69 cases (44.9%) and attendings detected at 
least one lesion in 27/59 cases (45.8%). There was also no significant 
difference between DCE and HD-WLC in lesion detection. There were 














1 14 14 
2 6 9 
3 2 5 
4 2 3 
5 3 0 
		








The data shows some promising indications regarding fellow 
involvement in procedures while also revealing signs that could be 
cause for caution. In general, the data from this study mirrors the 
results of similar research done in a broader population (Chapman et 
al., 2010). In terms of lesion detection, which is a key aspect of CRC 
screening colonoscopy, fellows appear to be on par with attendings. 
But, this level of proficiency comes at the cost of significantly 
increased TPT and associated higher doses of sedation medications 
being administered to patients. Assessing the short-term and long-
term impacts of these increased dosages on patients, as well as 
associated complications, could be a valuable area of future 
investigation. Also, future research is necessary to assess if the 
increased procedure time associated with fellow involvement is directly 
correlated to the increased sedation medication dosages during these 
procedures. One can envision a scenario in which the anesthesia 
provider titrates disproportionately more medications during fellow-
performed, attending-supervised procedures if the anesthesia provider 
expects that these procedures will have longer durations. 	
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It was not surprising that the majority of fellow-performed, 
attending-supervised procedures were executed by third-year fellows. 
In the structure of GI fellowship at BIDMC, third-year fellows have the 
most required endoscopy training hours and have the most experience 
doing procedures. Even though first-year fellows have a similar 
amount of required endoscopy training hours, it is understandable that 
third-year fellows performed so many of the procedures in this study 
given their increased experience and independence. 	
A weakness of the current research is that fellow involvement 
was not randomized. Due to the structure of the RCT from which data 
for this study was obtained, randomization only took place in terms of 
assigning DCE or HD-WLC. Therefore, the data from this study cannot 
conclude that fellow involvement led to any of the outcomes observed 
but rather was associated with those outcomes. Without randomization 
of fellow involvement, there are many possible explanations for the 
observed outcomes. For example, it is possible that fellows chose to 
involve themselves in cases that were more complex or medically 
intriguing, which could lead to increased TPT regardless of the level of 
clinician experience. However, at BIDMC, fellows typically do not select 
cases, but rather perform all procedures on the attending’s schedule 
so this risk of bias is likely reduced but cannot be fully excluded.	
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One key finding of this research, which has been identified in 
other studies as well, is the questionable efficacy of DCE (Yang et al., 
2019). DCE procedures take longer for all clinicians to perform, 
especially fellows, and are not associated with enhanced lesion 
detection. Further research is needed to evaluate possible benefits of 
DCE and to answer questions regarding whether this type of procedure 
is more worthwhile compared to traditional HD-WLC. 	
In summary, the present study intends to meaningfully 
contribute to the field of gastroenterology and to inform conversations 
regarding patient safety, clinician training, colonoscopy techniques, 
and IBD care. It is up to every stakeholder—patients, trainees, and 
experienced clinicians—to make decisions that best serve the patients 
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